Axonis Therapeutics

Axonis built a proprietary discovery engine to unlock the neuro-blockbuster drug potential for KCC2 treatments of neurological disorders.

KCC2 is a genetically validated target for epilepsy and autism spectrum disorder. KCC2 mutations have also been linked to psychiatric conditions.

The Massachusetts Life Sciences Center (MLSC) named Axonis, Inc. CEO Joanna Stanicka a 2020 winners of the Massachusetts Next Generation

Axonis Therapeutics Announces $115 Million Series A Financing -- Oversubscribed financing brings together leading syndicate of life sciences investors

The International Space Station (ISS) U.S. National Laboratory and Boeing have partnered for the sixth consecutive year to provide up to $500,000 in

Axonis won the latest Innovation Prize in Boston for its work in neuro-restorative research in spinal cord injury.

AXONIS' Board of Directors is comprised of world-leading innovators, serial entrepreneurs, drug developers, scientists and patient advocates.

Jeff Stevens is a board observer, vice president at Alexandria Venture Investments, and head of Alexandria LaunchLabs; he was previously vice president of growth operations and strategy.

Jonathan Leff, M.D., is an executive partner in private equity at Sofinnova Investments and has over 29 years of clinical development experience.

AXONIS' executive team includes co-founders Joanna Stanicka, Ph.D., and Shane Hegarty, Ph.D., as well as its CMO and COO.

Axonis' scientific approach addresses patients' drug resistance and disabling side effects from these first-line medications.

Axonis Therapeutics, Inc. 75 Kneeland Street, 14th Fl. Boston, MA 02111 Linkedin

Axonis Therapeutics is a Boston-based biotechnology company developing neuromedicines targeting KCC2.